Brochure
More information from http://www.researchandmarkets.com/reports/1595712/
Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic
Breast Cancer: US Oncologist Survey
Description: Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.
Patient case highlights:
In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive
HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose…
In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with…
Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing -directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer. Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
- Understand what occurs with actual patients - Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies - Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget - Understand where your product fits
- Understand where your competitor's product fits
Contents: Executive Summary Chapter 1: Introduction
Table 1. Treatment Options in Metastatic Breast Cancer Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation Figure 2.1 Gender of Survey Respondents Figure 2.2 Years since Medical School Graduation Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State's Breast Cancer Mortality Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen Chapter 3: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer
metastatic breast cancer
Figure 3.3 Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.4 Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Factors Influencing Treatment Choice with ER/PR positive HER2/neu Negative Metastatic Breast Cancer Figure 3.5 Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer Chapter 4: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer with Comorbidities Figure 4.1 Confidence managing patient with metastatic breast cancer with multiple comorbidities Figure 4.2 Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 4.3 Treatment in addition to the aromatase inhibitor for patient's metastatic breast cancer with multiple comorbidities
Figure 4.4 Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities Figure 4.5 Factors influencing treatment for progressive metastatic breast cancer with multiple
comorbidities Chapter 5: Summary
Appendix A: Survey Instrument
Ordering: Order Online - http://www.researchandmarkets.com/reports/1595712/
Order by Fax - using the form below
Order by Post - print the order form below and send to Research and Markets,
Guinness Centre, Taylors Lane, Dublin 8, Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Formats
Please select the product formats and quantity you require:
* Shipping/Handling is only charged once per order.
Contact Information
Please enter all the information below in BLOCK CAPITALS
Product Name: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey
Web Address: http://www.researchandmarkets.com/reports/1595712/
Office Code: SC
Quantity
CD-ROM: USD 500 + USD 56 Shipping/Handling Hard Copy: USD 500 + USD 56 Shipping/Handling Electronic (PDF)
-Single User: USD 500
Electronic (PDF)
-Enterprisewide: USD 600
Title: Mr Mrs Dr Miss Ms Prof
First Name: Last Name:
Email Address: * Job Title: Organisation: Address: City:
Postal / Zip Code: Country:
Phone Number: Fax Number:
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
Pay by credit card: You will receive an email with a link to a secure webpage to enter yourcredit card details.
Pay by check: Please post the check, accompanied by this form, to: Research and Markets,
Guinness Center, Taylors Lane, Dublin 8, Ireland.
Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083 Bank Address Ulster Bank,
27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
